Navigation
Company
The Company
Leadership
Board of Directors
Our Science
mTOR Pathway
TSC1
&
TSC2
nab
Technology Platform
Publications and Abstracts
Our Medicine
Our Medicine
Advanced Malignant PEComa
Expanded Access
Pipeline
Patients
Overview
Patient Advocacy
Clinical Trials
Investors & News
IR Overview
Stock
Stock Quote & Chart
Analyst Coverage
Press Releases
Event Calendar
Presentations
Corporate Presentations
Scientific Presentations
Financial
SEC Filings
Financial Reports
Quarterly Results
Forms
Governance
Governance Highlights
Committee Composition
IR Resources
Investor FAQ
Information Request
Email Alerts
IR Contacts
Contact Us
General Contact
For Healthcare Professionals
Careers
Institutional experience with
nab
-sirolimus in patients with malignancies harboring
TSC1
or
TSC2
mutations
Home
Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations
Next Post
Previous Post
Institutional experience with
nab
-sirolimus in patients with malignancies harboring
TSC1
or
TSC2
mutations
June 4, 2021
/
Publications
Like
this post!
Share
the Post
About
the Author
Related
Posts
Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO™ for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa
Phase 2 study of
nab
-sirolimus in patients with well-differentiated and advanced/metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas
Aadi Bioscience Initiates Rolling Submission of NDA to FDA for nab-sirolimus (ABI-009, FYARRO™) for the Treatment of Advanced Malignant PEComa
Improved tumor penetration, anti-tumor activity, and survival of ABI-009 (
nab
-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition
Study-end analysis from AMPECT, an open-label, phase 2 registration trial of patients with advanced malignant PEComatreated with
nab
-sirolimus, showing durability of response and long-term safety
Severe Pulmonary Arterial Hypertension Treated with ABI-009,
nab
-Sirolimus, an mTOR Inhibitor
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
Comments
Comments are closed.
Next Post
Previous Post
Comments
Comments are closed.